Tocilizumab

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

TAKAYASU ARTERITIS

Conditions

TAKAYASU ARTERITIS

Trial Timeline

Jun 10, 2014 → Feb 1, 2019

NCT ID

NCT02101333

About Tocilizumab

Tocilizumab is a phase 3 stage product being developed by Chugai Pharmaceutical for TAKAYASU ARTERITIS. The current trial status is completed. This product is registered under clinical trial identifier NCT02101333. Target conditions include TAKAYASU ARTERITIS.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02101333	Phase 3	Completed	Jun 10, 2014	Feb 1, 2019	TAKAYASU ARTERITIS

Competing Products

1 competing product in TAKAYASU ARTERITIS

See all competitors

Product	Company	Stage	Hype Score
Upadacitinib + Placebo for Upadacitinib + Prednisolone	AbbVie	Phase 3	77

Other Products from Chugai Pharmaceutical

Satralizumab 120 mgApproved

Pegasys® + Pegasys®Approved

ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboPhase 3

R744 + Epoetin betaPhase 3

EmicizumabPhase 3